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Abstract: Urinary tract infections (UTIs) are a serious healthcare dilemma influencing 
millions of patients every year and represent the second most frequent type of body 
infection. Pseudomonas aeruginosa is a multidrug-resistant pathogen causing numerous 
chronic biofilm-associated infections including urinary tract, nosocomial, and medical 
devices-related infections. In the present study, the biofilm of P. aeruginosa CCIN34519, 
recovered from inpatients with UTIs, was established on polystyrene substratum and 
scanning electron microscopy (SEM) and was utilized for visualization of the biofilm. A 
previously described in vitro system for real-time monitoring of biofilm growth/inhibition 
was utilized to assess the antimicrobial effects of ciprofloxacin, levofloxacin, moxifloxacin, 
norfloxacin, ertapenem, ceftriaxone, gentamicin, and tobramycin as single antibiotics as 
well as in combinations with zinc sulfate (2.5 mM) against P. aeruginosa CCIN34519 
biofilm. Meanwhile, minimum inhibitory concentrations (MICs) at 24 h and mutant 
prevention concentrations (MPCs) at 96 h were determined for the aforementioned 
antibiotics. The real-time monitoring data revealed diverse responses of P. aeruginosa 
CCIN34519 biofilm to the tested antibiotic-zinc sulfate combinations with potential 
synergisms in cases of fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, and 
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norfloxacin) and carbapenem (ertapenem) as demonstrated by reduced MIC and MPC 
values. Conversely, considerable antagonisms were observed with cephalosporin (ceftriaxone) 
and aminoglycosides (gentamicin, and tobramycin) as shown by substantially increased 
MICs and MPCs values. Further deliberate in vivo investigations for the promising 
synergisms are required to evaluate their therapeutic potentials for treatment of UTIs 
caused by P. aeruginosa biofilms as well as for developing preventive strategies. 
Keywords: biofilm; Pseudomonas aeruginosa; zinc sulfate; urinary tract infection; 
fluoroquinolone; synergism 
 
Abbreviations 
CLSI Clinical and Laboratory Standards Institute 
MIC Minimum Inhibitory Concentration 
MPC Mutant Prevention Concentration 
NAUTICA North American Urinary Tract Infection Collaborative Alliance 
OTC Over The Counter 
P. aeruginosa Pseudomonas aeruginosa 
SEM Scanning Electron Microscope 
UTI Urinary Tract Infection 
1. Introduction 
Biofilm associated infections tend to be reluctant and difficult to eradicate [1]. The increased 
antibiotic resistance of biofilms was generally attributed to the biofilm-associated patterns of gene 
expression, slow growth rate, and substantially diminished antimicrobial diffusion within the biofilm [2]. 
Biofilms are considered relevant to the clinical settings because they play key roles in the ability of 
biofilm-ensconced bacteria to tolerate relatively high therapeutic doses of antibiotics and persist in 
chronic infections [3,4]. Urinary tract infections (UTIs) are one of the most common bacterial 
infections affecting humans all through their life period [5,6]. UTIs are responsible for more than eight 
million visits to clinicians and more than two million admissions to the emergency rooms in the United 
States annually [6,7]. Furthermore, UTIs are the most common urological disease in the United States, 
with a financial burden on the healthcare system exceeding $3.5 billion annually [8]. 
Pseudomonas aeruginosa is an important opportunistic human pathogen and is eminent for chronic 
infections including medical device-associated infections as well as urinary tract infections [9]. The 
urinary tract infection (UTI) caused by P. aeruginosa is a serious health problem affecting millions of 
people worldwide each year and catheterization of the urinary tract is one of the most common 
predisposing factors to such infections [6]. Indisputably, biofilm formation was considered to be the 
key feature of P. aeruginosa survival in chronic infections, and extracellular matrices of the biofilms 
provide structural scaffold and protective barricade against antibiotics [10,11]. In P. aeruginosa 
biofilm, the efficacy of the antimicrobial chemotherapy may be attenuated not only by deficiency of 
antibiotics access caused by the sheltered bacteria within the exopolysaccharide alginate matrix but 
also by emergence of the mutant subpopulations [12]. 
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Fluoroquinolones, β-lactams and aminoglycosides are the main classes of antibiotics used for 
treatment of P. aeruginosa infections. Unfortunately, the multi-drug resistant isolates of P. aeruginosa 
which patients are often exposed to in hospital settings are resistant to one or more of these antibiotic 
classes [13–17]. Selective pressure due to excessive exposure of bacteria to antibiotics is generally the 
origin of such high incidence of resistance in the hospitals environment. Intensive care units (ICU) and 
long-term care facilities are also notorious worldwide for harboring multi-drug and pan-drug resistant  
P. aeruginosa strains [17,18]. Owing to the unmet medical needs of novel antimicrobial agents [19,20], 
the use of combination therapy has gained attention as an option strategy for combating P. aeruginosa 
biofilm associated infections [21–23]. Zinc is a vital trace element required for virtually all forms of 
life [24]. It is also essential for all bacteria, but surplus amounts of the metal can possess toxic effects 
on them [25] and zinc chelation with nitroxoline, a urinary antibiotic, induced the dispersal of  
P. aeruginosa biofilms [26]. In this context, the objective of the current study was to evaluate the 
antimicrobial interactions of different fluoroquinolones, carbapenem, cephalosporin, and aminoglycosides 
with zinc sulfate against biofilm of the uro-pathogen, P. aeruginosa CCIN34519, through implementation 
of in vitro real-time monitoring system. 
2. Results and Discussion 
2.1. Scanning Electron Microscopy of the Biofilm 
Variable pressure scanning electron microscopy was used for visualization of the biofilm on polystyrene 
plates after 12 h of incubation in absence of physical distortion or gold coating of the biofilm. The 
SEM demonstrated a well-established P. aeruginosa CCIN34519 biofilm as shown in Figure 1. 
Figure 1. Colored scanning electron micrograph illustrating the appearance of P. aeruginosa 
CCIN34519 biofilm on polystyrene substratum. 
 
2.2. Real-Time Monitoring of P. aeruginosa CCIN34519 Biofilm 
The effect of different concentrations of ciprofloxacin (0.1–1.6 µg/mL) alone on P. aeruginosa 
CCIN34519 biofilm as compared to the control (cation adjusted Mueller Hinton II; CAMH broth) is 
shown in Figure 2a. The minimum inhibitory concentration (MIC) and mutant prevention concentration 
(MPC) of ciprofloxacin against P. aeruginosa CCIN34519 biofilm, as determined by kinetic measurements 
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by means of the Bioscreen C, were 0.8 µg/mL at 24 h and 1.6 µg/mL at 96 h, respectively. Real-time 
monitoring data showed that ciprofloxacin alone inhibited the biofilm growth for 4, 8, 20, and 38 h 
with the tested concentration levels of 0.1, 0.2, 0.4, and 0.8 µg/mL, respectively. For the untreated 
biofilm, microbial growth from P. aeruginosa CCIN34519 biofilm exponentially increased and 
reached the peak at 10 h of incubation, followed by a gradual decline for up to 35 h, and finally 
maintained the plateau until the end of the experiment (Figure 2a). In this study, zinc sulfate 
concentration (2.5 mM) was selected as the highest concentration that had no inhibitory effect on the 
growth of P. aeruginosa CCIN34519 biofilm as shown in Figure 2b. In the presence of zinc sulfate 
(2.5 mM), the MIC and MPC of ciprofloxacin against P. aeruginosa CCIN34519 biofilm decreased to 
0.2 µg/mL at 24 h and 0.4 µg/mL at 96 h, respectively. Furthermore, ciprofloxacin could inhibit the 
biofilm growth for 17 and 60 h at concentration levels of 0.1, and 0.2 µg/mL, respectively (Figure 2b). 
Figure 2. Real-time data showing the effect of (a) Ciprofloxacin alone (0.1–1.6 µg/mL) 
and (b) Ciprofloxacin (0.1–1.6 µg/mL) in combination with zinc sulfate (2.5 mM) on  
P. aeruginosa CCIN34519 biofilm as monitored by the Bioscreen C over 96 h. Control 
represents cation adjusted Mueller Hinton II broth (CAMH) while, ZnSO4 indicates 
CAMH broth supplemented with 2.5 mM zinc sulfate. 
 
(a) 
 
(b) 
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The MIC and MPC of levofloxacin against P. aeruginosa CCIN34519 biofilm were 4.0 µg/mL and 
8.0 µg/mL, respectively, and levofloxacin alone inhibited the biofilm growth for 18, 22, and 30 h with 
the concentration levels of 1.0, 2.0, and 4.0 µg/mL, respectively (Figure 3a). On the other hand, the 
MIC and MPC of levofloxacin, in the presence of zinc sulfate (2.5 mM), were curtailed to 0.25 µg/mL 
and 0.5 µg/mL, respectively. Furthermore, levofloxacin inhibited the biofilm growth for 20 and 36 h at 
concentration levels of 0.13, and 0.25 µg/mL, respectively (Figure 3b). 
Figure 3. Real-time data showing the effect of (a) Levofloxacin alone (0.13–8.00 µg/mL) 
and (b) Levofloxacin (0.13–8.00 µg/mL) in combination with zinc sulfate (2.5 mM) on  
P. aeruginosa CCIN34519 biofilm as monitored by the Bioscreen C over 96 h. Control 
represents cation adjusted Mueller Hinton II broth (CAMH) while, ZnSO4 indicates 
CAMH broth supplemented with 2.5 mM zinc sulfate. 
 
(a) 
 
(b) 
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For moxifloxacin, the MIC and MPC of against P. aeruginosa CCIN34519 biofilm, as determined 
by kinetic measurements, were 16 µg/mL and 32 µg/mL, respectively. Real-time monitoring data 
demonstrated that moxifloxacin alone suppressed the biofilm growth for 15 and 50 h with the tested 
concentration levels of 8 and 16 µg/mL, respectively (Figure 4a). In the presence of zinc sulfate  
(2.5 mM), the MIC and MPC of moxifloxacin against P. aeruginosa CCIN34519 biofilm reduced to 
2.0 µg/mL and 8.0 µg/mL, respectively. Furthermore, moxifloxacin could inhibit the biofilm growth 
for up to 20, 32 and 58 h at concentration levels of 1.0, 2.0 and 4.0 µg/mL, respectively (Figure 4b). 
Figure 4. Real-time data showing the effect of (a) Moxifloxacin alone (1.0–32.0 µg/mL) 
and (b) Moxifloxacin (1.0–32.0 µg/mL) in combination with zinc sulfate (2.5 mM) on  
P. aeruginosa CCIN34519 biofilm as monitored by the Bioscreen C over 96 h. Control 
represents cation adjusted Mueller Hinton II broth (CAMH) while, ZnSO4 indicates 
CAMH broth supplemented with 2.5 mM zinc sulfate. 
 
(a) 
 
(b) 
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Regarding norfloxacin, the MIC and MPC against P. aeruginosa CCIN34519 biofilm were  
5.0 µg/mL and 10.0 µg/mL, respectively. Norfloxacin suppressed the biofilm slightly above the 
baseline and completely at the baseline for 28 and 47 h at concentration levels of 2.5 and 5.0 µg/mL, 
respectively and its lower concentrations (0.63–1.25 µg/mL) could not suppress the biofilm (Figure 5a). 
On the other hand, the MIC and MPC of norfloxacin, in the presence of zinc sulfate (2.5 mM), 
diminished to 1.25 µg/mL and 2.5 µg/mL, respectively. Furthermore, norfloxacin inhibited the biofilm 
growth for 26 and 96 h at concentration levels of 1.25 and 2.5 µg/mL, respectively (Figure 5b). 
Figure 5. Real-time data showing the effect of (a) Norfloxacin alone (0.63–10.0 µg/mL) 
and (b) Norfloxacin (0.63–10.0 µg/mL) in combination with zinc sulfate (2.5 mM) on  
P. aeruginosa CCIN34519 biofilm as monitored by the Bioscreen C over 96 h. Control 
represents cation adjusted Mueller Hinton II broth (CAMH) while, ZnSO4 indicates 
CAMH broth supplemented with 2.5 mM zinc sulfate. 
 
(a) 
 
(b) 
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The MIC and MPC of ertapenem against P. aeruginosa CCIN34519 biofilm maintained the same 
value of 20 µg/mL. Real-time data demonstrated that ertapenem alone suppressed the biofilm growth 
for 5 and 10 h at concentration levels of 5 and 10 µg/mL, respectively. Moreover, both concentrations 
markedly abridged the biofilm growth for up to 30 h and the biofilm maintained a prominent low level 
of microbial growth from 30–96 h of incubation with ertapenem (10 µg/mL) as compared to the 
control (Figure 6a). In the presence of zinc sulfate (2.5 mM), both MIC and MPC of ertapenem against 
P. aeruginosa CCIN34519 biofilm reduced to 10 µg/mL. Furthermore, ertapenem inhibited the biofilm 
growth for up to 5 and 96 h at concentration levels of 5 and 10 µg/mL, respectively and the biofilm 
showed a marked reduction of the microbial growth over 96 h with ertapenem (5 µg/mL) as compared 
to the control (Figure 6b). 
Figure 6. Real-time data showing the effect of (a) Ertapenem alone (5.0–40.0 µg/mL) and 
(b) Ertapenem (5.0–40.0 µg/mL) in combination with zinc sulfate (2.5 mM) on  
P. aeruginosa CCIN34519 biofilm as monitored by the Bioscreen C over 96 h. Control 
represents cation adjusted Mueller Hinton II broth (CAMH) while, ZnSO4 indicates 
CAMH broth supplemented with 2.5 mM zinc sulfate. 
 
(a) 
 
(b) 
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Concerning ceftriaxone, the MIC and MPC against P. aeruginosa CCIN34519 biofilm were  
80 µg/mL and 640 µg/mL, respectively. Depending on the kinetic data, ceftriaxone alone inhibited the 
biofilm growth for 20, 28, 48, and 57 h with the tested concentration levels of 40, 80, 160, and 320 µg/mL, 
respectively (Figure 7a). Conversely, the MIC and MPC of ceftriaxone, in presence of zinc sulfate  
(2.5 mM), considerably increased to 320 µg/mL and >640 µg/mL, respectively. Additionally, 
ceftriaxone-zinc sulfate (2.5 mM) combination could inhibit the biofilm growth for up to 5, 8, 16, 40, 
and 72 h at concentration levels of 40, 80, 160, 320, and 640 µg/mL, respectively, but none of the tested 
ceftriaxone concentrations could suppress P. aeruginosa CCIN34519 biofilm over 96 h (Figure 7b). 
Figure 7. Real-time data showing the effect of (a) Ceftriaxone alone (40–640 µg/mL) and 
(b) Ceftriaxone (40–640 µg/mL) in combination with zinc sulfate (2.5 mM) on  
P. aeruginosa CCIN34519 biofilm as monitored by the Bioscreen C over 96 h. Control 
represents cation adjusted Mueller Hinton II broth (CAMH) while, ZnSO4 indicates 
CAMH broth supplemented with 2.5 mM zinc sulfate. 
 
(a) 
 
(b) 
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With gentamicin, the MIC and MPC against P. aeruginosa CCIN34519 biofilm maintained the 
same value of 12.5 µg/mL. Gentamicin suppressed the biofilm to some extent above the baseline and 
entirely at the baseline for 20 and 96 h at concentration levels of 6.25 and 12.5 µg/mL, respectively 
and its lower concentrations (1.56–3.13 µg/mL) could not suppress the biofilm (Figure 8a). On the 
contrary, the MIC and MPC of gentamicin, in presence of zinc sulfate (2.5 mM), substantially 
increased to 25 µg/mL and 50 µg/mL, respectively. Furthermore, gentamicin partially suppressed the 
biofilm growth, parallel to the baseline at 6.25 and 12.5 µg/mL for 18 and 30 h, respectively, but 
completely inhibited it at 25 µg/mL for 75 h. Lower concentrations of gentamicin (1.56–3.13 µg/mL) 
in combination with zinc sulfate (2.5 mM) could not inhibit the biofilm and demonstrated higher 
growth rate over the initial 10 h of the incubation period as compared to that of gentamicin alone 
(Figure 8b). 
Figure 8. Real-time data showing the effect of (a) Gentamicin alone (1.56–50.0 µg/mL) 
and (b) Gentamicin (1.56–50.0 µg/mL) in combination with zinc sulfate (2.5 mM) on  
P. aeruginosa CCIN34519 biofilm as monitored by the Bioscreen C over 96 h. Control 
represents cation adjusted Mueller Hinton II broth (CAMH) while, ZnSO4 indicates 
CAMH broth supplemented with 2.5 mM zinc sulfate. 
 
(a) 
 
(b) 
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Regarding tobramycin, the MIC and MPC against P. aeruginosa CCIN34519 biofilm were  
4.0 µg/mL and 8.0 µg/mL, respectively. Tobramycin alone could inhibit the biofilm growth for 22 and 
64 h at concentration levels of 2.0 and 4.0 µg/mL, respectively (Figure 9a). Quite the opposite, the 
MIC and MPC of tobramycin, in the presence of zinc sulfate (2.5 mM), noticeably increased to  
16 µg/mL and 32 µg/mL, respectively. Moreover, tobramycin partially suppressed the biofilm growth 
at 8.0 µg/mL for 22 h and completely inhibited it at 16 µg/mL for 76 h. Similar to gentamicin, lower 
concentrations of tobramycin (1.0–4.0 µg/mL) in combination with zinc sulfate (2.5 mM) could not 
inhibit the biofilm and showed a higher growth rate over the initial 12 h of the incubation period as 
compared to that of tobramycin alone (Figure 9b). 
Figure 9. Real-time data showing the effect of (a) Tobramycin alone (1.0–32.0 µg/mL) 
and (b) Tobramycin (1.0–32.0 µg/mL) in combination with zinc sulfate (2.5 mM) on  
P. aeruginosa CCIN34519 biofilm as monitored by the Bioscreen C over 96 h. Control 
represents cation adjusted Mueller Hinton II broth (CAMH) while, ZnSO4 indicates 
CAMH broth supplemented with 2.5 mM zinc sulfate. 
 
(a) 
 
(b) 
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The synergistic and antagonistic effects of zinc sulfate (2.5 mM) on different tested antibiotics 
against P. aeruginosa CCIN34519 biofilm are summarized in Table 1. 
Table 1. Effects of zinc sulfate on different antibiotics minimum inhibitory concentrations 
(MICs) and mutant prevention concentrations (MPCs) against P. aeruginosa  
CCIN34519 biofilm. 
Antibiotic Class 
Biofilm Without Zinc Sulfate Biofilm With Zinc Sulfate * Anti-biofilm Efficacy 
of Combination MIC (24 h) MPC (96 h) MIC (24 h) MPC (96 h) 
Ciprofloxacin Fluoroquinolone 0.8 1.6 0.20 0.40 Synergistic 
Levofloxacin Fluoroquinolone 4.0 8.0 0.25 0.50 Synergistic 
Moxifloxacin Fluoroquinolone 16 32 2.0 8.0 Synergistic 
Norfloxacin Fluoroquinolone 5.0 10 1.25 2.5 Synergistic 
Ertapenem Carbapenem 20 20 10 10 Synergistic 
Ceftriaxone Cephalosporin 80 640 320 > 640 Antagonistic  
Gentamicin Aminoglycoside 12.5 12.5 25 50 Antagonistic 
Tobramycin Aminoglycoside 4.0 8.0 16 32 Antagonistic 
* Zinc sulfate concentration (2.5 mM); MIC = Minimum Inhibitory Concentration; MPC = Mutant 
Prevention Concentration. 
According to the MICs interpretive standards stated by Clinical and Laboratory Standards Institute 
(CLSI) [27], P. aeruginosa CCIN34519 biofilm were susceptible to ciprofloxacin and tobramycin; of 
intermediate resistance to levofloxacin, norfloxacin and gentamicin; and resistant to moxifloxacin, 
ertapenem and ceftriaxone. Concerning MPC at 96 h, P. aeruginosa CCIN34519 biofilm was 
considered to demonstrate intermediate resistance to ciprofloxacin, norfloxacin, gentamicin and 
tobramycin; and be resistant to levofloxacin, moxifloxacin, ertapenem and ceftriaxone. In the presence 
of zinc sulfate (2.5 mM), P. aeruginosa CCIN34519 biofilm was susceptible to ciprofloxacin, 
levofloxacin, moxifloxacin and norfloxacin; demonstrate intermediate resistance to ertapenem; and be 
resistant to ceftriaxone, gentamicin, and tobramycin. On the other hand, at 96 h and in combination 
with zinc sulfate (2.5 mM), P. aeruginosa CCIN34519 biofilm maintained its susceptibilities to 
ciprofloxacin, levofloxacin and norfloxacin; revealed intermediate resistance to moxifloxacin, and 
ertapenem; and showed resistance to ceftriaxone, gentamicin, and tobramycin. 
2.3. Discussion 
Bacterial biofilms represent global and predominant causes of both chronic infections and 
indwelling medical devices associated infections such as catheters and prostheses. Such infections 
typically exhibit significantly enhanced resistance to antimicrobial agents rendering them challenging 
to treat using conventional chemotherapeutic agents [28]. Standard doses of the antibiotic therapy can 
reduce the biofilm but rarely eradicates the entire biofilm [29,30]. Some theories attributed the 
antimicrobial resistance of the biofilm to its physical architecture, mutations, and altered gene 
expression patterns [31–33]. P. aeruginosa is one of the predominant causes of UTIs, nosocomial and 
intensive care unit-associated infections that occur annually worldwide [6,34]. As a consequence of 
biofilm formation, frequency of the resistant P. aeruginosa isolates present in clinical settings has been 
radically increased, thereby mandating the development of alternative therapeutic strategies [35].  
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In this context, P. aeruginosa biofilms have demonstrated resistance to different classes of antibiotics 
including ciprofloxacin (fluoroquinolone), ceftazidime (cephalosporin), and tobramycin (aminoglycoside) 
at concentrations far superior to the therapeutically achievable concentrations [36,37] and one 
hypothesis explaining biofilm resistance proposes the existence of the persister cells within the biofilm 
which are metabolically inactive and consequently are not destroyed by antimicrobial agents [38–41]. 
In the current study, the results of the SEM revealed that P. aeruginosa CCIN34519 biofilm could 
extensively colonize the polystyrene substratum within 12 h of incubation as well as to develop a 
relatively uniform architecture. Some investigators reported that a thick P. aeruginosa biofilm on 
surface of the polyethylene tubing was observed by SEM at 48 h in their in vivo experiments and 
repeatable pattern of cell death and lysis has been shown in P. aeruginosa biofilm during its 
development [42]. The difference in time of the biofilm establishment may be attributed to the 
experimental design and strain difference as well as nature of the used substrata. Main factors 
influencing the biofilm development may include temperature, nutrient composition, aeration, flow 
rate, and history of the cultures used for the inoculation, thus the experimental reproducibility can be 
extensively improved if these factors have been considered [43]. In the present study, the above 
mentioned variables were efficiently controlled in the conducted experiments through utilizing the 
Bioscreen C technology.  
It has been demonstrated that P. aeruginosa isolates were more resistant to growth inhibition by 
antibiotics when grown in biofilm cultures than when grown in planktonic ones [44,45]. For that 
reason, the failure of conventional planktonic culture techniques to predict antibiotic susceptibilities 
may explain inability of the antimicrobial agents to eradicate P. aeruginosa biofilm-associated UTIs. 
In view of that, all the experiments in this study were carried on the biofilm of P. aeruginosa 
CCIN34519 strain recovered from hospitalized patients with urinary tract infection through NAUTICA 
study [46]. 
It was previously reported that zinc oxide showed antibacterial and antifungal activity against 
planktonic cultures of some tested micro-organisms in a concentration dependent manner [47]. 
Moreover, complexed zinc with protoporphyrin IX or mesoprotoporphyrin IX were both highly 
effective in negating planktonic growth and biofilm formation of some tested bacteria and these  
zinc complexes act as iron siderophore analogs by supplanting the natural iron uptake of the tested 
bacteria [48]. P. aeruginosa regulates multiple genes by the zinc-dependent DksA transcriptional 
regulator at low zinc conditions. Nevertheless, excess amounts of this trace element can be potentially 
lethal for the bacteria. Thus, most bacteria have developed systems for both zinc acquisition and 
detoxification [25]. Concerning the MIC values in this study, zinc sulfate (2.5 mM) could increase the 
efficacies of ertapenem, ciprofloxacin, levofloxacin, moxifloxacin, and norfloxacin by 2, 4, 16, 8, and 
4 folds, respectively, but decreased the efficacies of ceftriaxone, gentamicin, and tobramycin by 4, 2, 
and 4 folds, respectively, on P. aeruginosa CCIN34519 biofilm. Previous studies mentioned that doses 
of the antibiotics required to inhibit or eradicate the established biofilms frequently exceed the 
maximum achievable plasma concentrations for such antibiotics [44,45] and retention of the antibiotics 
in the anti-pseudomonal cache is a critical issue throughout the world as there is a limited number of 
effective drugs for treatment of P. aeruginosa infections [49]. Generally, fluoroquinolones have a 
broad spectrum of antimicrobial coverage and ciprofloxacin and, in particular, is one of the relatively 
effective antibiotics against P. aeruginosa infections in clinical settings [50,51]. Although  
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P. aeruginosa CCIN34519 biofilm revealed no susceptibility at 96 h to all the tested antibiotics, the 
biofilm maintained its susceptibility to three fluoroquinolones (ciprofloxacin [MPC = 0.4 µg/mL], 
levofloxacin [MPC = 0.5 µg/mL], and norfloxacin [MPC = 2.5 µg/mL]) out of the eight tested 
antibiotics in the presence of zinc sulfate (2.5 mM) reserving such drugs as effective agents and  
within the therapeutically achievable concentrations for treatment of P. aeruginosa CCIN34519 
biofilm in UTIs. 
Prior to mutant selection or acquisition of exogenous resistance, P. aeruginosa possesses powerful 
efflux pumps to eliminate almost all classes of antibiotics [49,52] and the concept of its being a super 
bug was built on such a foundation [13]. The reported MPCs for some fluoroquinolones against  
P. aeruginosa ranged from 2 to >32.0 µg/mL depending on the study and the bacterial genotype. 
Nevertheless, the first-step par C gene mutation dramatically increases the MPC far above the original 
MPC [53–56]. Consistent with these findings, MPCs of the tested fluoroquinolones in this study 
ranged from 1.6–32.0 µg/mL against P. aeruginosa CCIN34519 biofilm. On the other hand, range of 
the MPCs for such fluoroquinolones prominently decreased to 0.4–8.0 µg/mL in combination with 
zinc sulfate (2.5 mM). In presence of zinc sulfate (2.5 mM), real-time data revealed that the tested 
fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, and norfloxacin) at lower concentrations 
(0.2, 0.25, 4.0, and 1.25 µg/mL, respectively) could suppress the growth of P. aeruginosa CCIN34519 
biofilm for longer periods of time (60, 36, 58, and 26 h, respectively) and ertapenem (5.0 µg/mL) 
noticeably reduced the biofilm growth as compared to such antibiotics alone at the same concentration 
levels. Consequently, these antibiotics may afford better antimicrobial coverage against P. aeruginosa 
biofilm for extended duration and within the same therapeutic doses in case of concomitant 
administrations with zinc sulfate. 
The potential for serious antagonistic effects by zinc sulfate (2.5 mM) combination with 
cephalosporin (ceftriaxone) or aminoglycosides (gentamicin and tobramicin) underscores the 
inevitability to circumvent the concomitant administration of over the counter (OTC) zinc sulfate 
containing preparations with the prescribed cephalosporins and aminoglycosides during the therapy of 
P. aeruginosa biofilm related infections such as nosocomial catheter-associated UTI as well as soft 
tissue infections. In the current study, the observed antagonism by zinc sulfate combination with 
gentamicin and tobramicin against P. aeruginosa CCIN34519 biofilm may be attributed to general 
interference of the divalent cations with the uptake of the aminoglycosides at both the outer and inner 
membranes in P. aeruginosa [57]. On the other hand, zinc sulfate (2.5 mM) demonstrated synergistic 
and antagonistic effects in combination with ertapenem and ceftriaxone, respectively. These 
paradoxical effects with the tested β-lactam antibiotics may be explained by the variable zinc affinities 
to different metallo-beta-lactamases [58]. Fortunately, the UTI patients infected with P. aeruginosa 
biofilm may possess an edge in overcoming the infection when ertapenem or fluoroquinolones 
(ciprofloxacin, levofloxacin, moxifloxacin, and norfloxacin) have been prescribed with simultaneous 
administration with zinc sulfate-containing preparations and such cases should be deliberately investigated. 
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3. Experimental 
3.1. Bacterial Strain and Antimicrobial Agents 
P. aeruginosa CCIN34519 strain used in this study was recovered from hospitalized patients with 
urinary tract infection through North American Urinary Tract Infection Collaborative Alliance 
(NAUTICA) study [46]. Before each experiment, P. aeruginosa CCIN34519 was sub-cultured on 
Mueller Hinton agar and incubated for 18–20 h at 37 °C. The inoculum was then prepared in  
cation-adjusted Mueller Hinton II broth (CAMH) and diluted to match 0.5 McFarland standard, which 
is equivalent to 1.5 × 10
8
 CFU/mL. Ceftriaxone sodium, ciprofloxacin hydrochloride, gentamicin 
sulfate, levofloxacin, moxifloxacin hydrochloride, norfloxacin, tobramycin, and zinc sulfate 
heptahydrate were purchased from Sigma-Aldrich (St. Louis, MO, USA). Ertapenem disodium powder 
was obtained from Thermo-Fisher Scientific (Waltham, MA, USA). All antibiotic stock solutions  
and dilutions were prepared according to the Clinical and Laboratory Standards Institute (CLSI) 
guidelines [27]. Stock solutions of the antibiotics were stored at −80 °C and aliquots of such solutions 
were thawed at room temperature and diluted in CAMH broth before each experiment. 
3.2. Scanning Electron Microscopy (SEM) 
For visualization of P. aeruginosa CCIN34519 biofilm, overnight broth culture of P. aeruginosa 
CCIN34519 in CAMH broth was diluted in PBS to 1.5 × 10
8
 CFU/mL using 0.5 McFarland equivalence 
turbidity standards (Thermo Scientific Remel™, Lenexa, KS, USA). The cell suspension was used to 
inoculate sterile CAMH broth at final bacterial count of 1.5 × 10
6
 CFU/mL and 1.5 mL aliquots of the 
inoculated broth was distributed in 24-well polystyrene plates (Corning Costar®, Corning, NY, USA). 
The plates were incubated for 12 h at 37 °C without shaking. After incubation, the supernatant was 
carefully decanted and the wells were washed twice with 2 mL PBS to remove the unattached or 
loosely attached bacterial cells. Fixation of P. aeruginosa CCIN34519 biofilm was conducted at 4 °C 
with 10% glutaraldehyde (Sigma-Aldrich) for 24 h. Subsequently, the wells were rinsed with a graded 
series (30%, 50%, 70%, and 100% v/v) of ethanol (Fisher Scientific, Waltham, MA, USA) for dehydration 
of biofilm specimens and the wells were then entirely air dried prior to SEM examinations [59]. The photo 
was captured using variable pressure JEOL scanning electron microscope (Model JSM-6490LV, 
Peabody, MA, USA) outfitted with a tungsten filament of 10 kV accelerating voltages and chamber 
variable pressure from 60–70 Pa. The adjustable pressure operation enables lower vacuum to exist at 
the sample chamber. This feature makes it possible to directly observe frozen or non-conductive 
specimens. The variable pressure chamber of JSM-6490LV also provides a positively ionized gas 
immediately above the specimen that in turn dissipates the negative charges that accumulate on the 
sample surface during scanning and interfere with image acquisition. In view of that, non-conductive 
biofilm specimens can be imaged without application of a conductive gold coating. 
3.3. Real-Time Monitoring of P. aeruginosa CCIN34519 Biofilm 
A previously described in vitro system for real-time monitoring of biofilm growth/inhibition [60] 
was utilized with minor adaptations to assess the antimicrobial effects of as single antibiotics as well as 
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in combinations with zinc sulfate (2.5 mM) against P. aeruginosa CCIN34519 biofilm. Initial log 
phase inocula (1 × 10
6
 CFU/mL) of P. aeruginosa CCIN34519 cultures were seeded (150 µL/well) 
into 100-well polystyrene honeycomb plates (Growth Curves USA, Piscataway, NJ, USA).  
P. aeruginosa CCIN34519 biofilms were allowed to develop in the incubator over 12 h at 37 °C. After 
incubation, each well of the honeycomb plates were carefully rinsed twice with 150 µL sterile saline 
for removal of planktonic cells using digital multichannel pipettor adapted for this system.  
Cation-adjusted Mueller Hinton II (CAMH) broths supplemented with two-fold escalating 
concentrations of ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ertapenem, ceftriaxone, 
gentamicin, and tobramycin as single antibiotics as well as in combinations with zinc sulfate (2.5 mM) 
were prepared and transferred to the established P. aeruginosa CCIN34519 biofilm (250 µL/well) in 
the honeycomb plates. Plates containing treated, untreated P. aeruginosa CCIN34519 biofilm, and 
negative controls were then placed in the preheated incubating chamber of the Bioscreen C which was 
programmed to maintain a temperature at 37 °C without shaking. Growth control wells of  
P. aeruginosa CCIN34519 biofilm treated with CAMH and CAMH spiked with zinc sulfate (2.5 mM) 
were also implemented in each experiment. Furthermore, negative controls containing CAMH only, 
CAMH spiked with zinc sulfate (2.5 mM), and CAMH broths supplemented with the above mentioned 
antibiotics as single agents as well as in combinations with zinc sulfate (2.5 mM) without the biofilm 
were also involved in the experiments to assure the sterility and stability of their optical density 
readings overall during 96 h of the incubation period. 
In real-time, P. aeruginosa CCIN34519 biofilm growth/inhibition was monitored using the 
automated technology of Bioscreen C (Growth Curves USA). The Bioscreen C monitors microbial 
growth through determining the optical densities in each well. Alterations in the optical densities due 
to the microbial growth or lysis from the biofilm were measured kinetically with an advanced 
photometrical technology of the Bioscreen C. A wide-band filter with spectrum range of 420–580 nm 
was used to measure the optical densities in all experiments. This filter has been utilized in the biofilm 
research because its sensitivity is not affected by the color transformation resulting from the growth  
of P. aeruginosa biofilm [60]. Each biofilm growth curve was repeated three times and the optical 
density values over 96 h were robotically recorded at 1 h intervals using EZExperiment software 
(Growth Curves USA) and exported to spread sheets for processing and graphical presentation. 
Minimum inhibitory concentration (MIC) of the biofilm was defined as the antibiotic concentration at 
which the optical density remains at the baseline (0.2–0.3) at the 24 h time point, while mutant 
prevention concentration (MPC) was reported as the antibiotic concentration that prevents growth and 
development of the resistant subpopulations from the biofilm at 96 h time point [60,61]. 
4. Conclusions 
This study demonstrated a heterogeneous range of anti-biofilm efficacies of the antibiotics in 
combination with zinc sulfate (2.5 mM) against P. aeruginosa CCIN34519 biofilm with potential 
synergisms in cases of fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin, and norfloxacin) 
and carbapenem (ertapenem) as demonstrated by the reduction of their MICs and MPCs. On the 
contrary, considerable antagonisms were observed with cephalosporin (ceftriaxone) and aminoglycosides 
(gentamicin, and tobramycin) as shown by the increment of their MICs and MPCs. Further deliberate 
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in vivo investigations for the promising synergisms are required to evaluate their therapeutic potentials 
for treatment of UTIs caused by P. aeruginosa biofilms. 
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